Beijing, China

Rucan Yan

This inventor holds 1 USPTO granted patent. Top assignee: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.. Active years: 2026.


% Patents Active = 100.0

Average Co-Inventor Count = 16.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Rucan Yan: Innovator in Pharmaceutical Technology

Introduction

Rucan Yan is a prominent inventor based in Beijing, China. He has made significant contributions to the field of pharmaceutical technology, particularly in the development of targeted lipid compounds. His work focuses on enhancing the efficiency and safety of drug delivery systems.

Latest Patents

Rucan Yan holds a patent for an "Extrahepatic targeted cationic lipid compound with high efficiency and low toxicity." This innovative compound is designed to improve the delivery of therapeutic or prophylactic agents. The patent outlines a compound of formula (I), or its N-oxide, solvate, pharmaceutically acceptable salt, or stereoisomer, which demonstrates high efficiency and low toxicity in its application.

Career Highlights

Rucan Yan is associated with Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. His role in the company has allowed him to focus on groundbreaking research and development in the pharmaceutical sector. His expertise has contributed to advancements in drug delivery technologies.

Collaborations

Rucan Yan has collaborated with notable colleagues, including Shuai Wang and Kai Dong. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of pharmaceutical technology.

Conclusion

Rucan Yan's contributions to the pharmaceutical industry through his innovative patent and collaborative efforts highlight his commitment to advancing drug delivery systems. His work continues to impact the field positively, paving the way for future innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…